EudraCT 2013-001010-14

Leids Universitair Medisch Centrum
NKI / A.v.L ziekenhuis Amsterdam

A study evaluating cabozantinib (XL184) versus everolimus in patients with a form of kidney cancer that has progressed after treatment with another therapy

Cabozantinib versus everolimus


Belangrijkste in/exclusiecriteria:
In: Must have received at least one VEGFR-targeting TKI (eg, sorafenib,sunitinib, axitinib, pazopanib or tivozanib). Prior treatment with other anticancer therapies including cytokines (eg, interleukin-2, interferonalfa),monoclonal antibodies, (eg, bevacizumab), and cytotoxic chemotherapy is allowed (except Exclusion Criterion #1),Karnofsky Performance Status (KPS) score of ≥ 70%,HbA1c ≤ 8%, must have radiographically progressed during treatment. Ex: Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor, or cabozantinib, receipt of any type of small molecule kinase inhibitor within 2 weeks before randomization, receipt of any type of anticancer antibody within 4 weeks before randomization, radiation therapy for bone metastasis within 2 weeks


Alle trials